Attached files

file filename
EX-32.1 - EX-32.1 - NUTRACEUTICAL INTERNATIONAL CORPa2203589zex-32_1.htm
EX-31.1 - EX-31.1 - NUTRACEUTICAL INTERNATIONAL CORPa2203589zex-31_1.htm

Use these links to rapidly review the document
Table of Contents

Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

for the Quarterly Period Ended March 31, 2011

Commission file number 000-23731

LOGO

NUTRACEUTICAL INTERNATIONAL CORPORATION
(Exact name of registrant as specified in its charter)

Delaware   87-0515089
(State of incorporation)   (IRS Employer Identification No.)

1400 Kearns Boulevard, 2nd Floor, Park City, Utah

 

84060
(Address of principal executive office)   (Zip code)

(435) 655-6106
(Registrant's telephone number, including area code)

        Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YES ý    NO o

        Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

YES o    NO o

        Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act:

Large accelerated filer o   Accelerated filer ý   Non-accelerated filer o
(Do not check if a
smaller reporting company)
  Smaller reporting company o

        Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES o    NO ý

At April 28, 2011, the registrant had 10,301,734 shares of common stock outstanding.


Table of Contents


NUTRACEUTICAL INTERNATIONAL CORPORATION

INDEX

Description
   
   
  Page No.  

Part I.

  Financial Information     3  

 

Item 1.

 

Financial Statements (unaudited)

   
3
 

     

Condensed Consolidated Balance Sheets—September 30, 2010 and March 31, 2011

   
3
 

     

Condensed Consolidated Statements of Operations and Comprehensive Income—Three Months And Six Months Ended March 31, 2010 and 2011

   
4
 

     

Condensed Consolidated Statements of Cash Flows—Six Months Ended March 31, 2010 and 2011

   
5
 

     

Notes to Condensed Consolidated Financial Statements

   
6
 

 

Item 2.

 

Management's Discussion and Analysis of Financial Condition and Results of Operations

   
13
 

 

Item 3.

 

Quantitative and Qualitative Disclosures about Market Risk

   
21
 

 

Item 4.

 

Controls and Procedures

   
21
 

Part II.

 

Other Information

   
22
 

 

Item 1.

 

Legal Proceedings

   
22
 

 

Item 1A.

 

Risk Factors

   
22
 

 

Item 2.

 

Unregistered Sales of Equity Securities and Use of Proceeds

   
22
 

 

Item 6.

 

Exhibits

   
22
 

2


Table of Contents

PART I—FINANCIAL INFORMATION

Item 1.    Financial Statements

        


NUTRACEUTICAL INTERNATIONAL CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited)

(dollars in thousands)

 
  September 30,
2010(1)
  March 31,
2011
 

ASSETS

             

Current assets

             
 

Cash and cash equivalents

  $ 3,740   $ 5,850  
 

Accounts receivable, net

    10,668     12,935  
 

Inventories, net

    40,273     38,528  
 

Prepaid expenses and other current assets

    2,107     1,865  
 

Deferred income taxes

    1,506     1,475  
           
   

Total current assets

    58,294     60,653  

Property, plant and equipment, net

   
61,733
   
66,233
 

Goodwill

    5,338     6,161  

Intangible assets, net

    19,671     20,143  

Other non-current assets

    2,115     2,633  

Deferred income taxes, net

    9,180     8,288  
           
   

Total assets

  $ 156,331   $ 164,111  
           

LIABILITIES AND STOCKHOLDERS' EQUITY

             

Current liabilities

             
 

Short-term debt

  $ 28,000   $  
 

Accounts payable

    10,621     13,393  
 

Accrued expenses

    7,052     5,660  
           
   

Total current liabilities

    45,673     19,053  

Long-term debt

   
   
27,000
 

Other non-current liabilities

    1,739     1,499  
           
   

Total liabilities

    47,412     47,552  
           

Stockholders' equity

             
 

Common stock

    104     103  
 

Additional paid-in capital

    23,408     22,386  
 

Retained earnings

    85,134     93,633  
 

Accumulated other comprehensive income

    273     437  
           
   

Total stockholders' equity

    108,919     116,559  
           
   

Total liabilities and stockholders' equity

  $ 156,331   $ 164,111  
           

(1)
The condensed consolidated balance sheet as of September 30, 2010 has been prepared using information from the audited financial statements at that date.

The accompanying notes are an integral part of these condensed consolidated financial statements.

3


Table of Contents


NUTRACEUTICAL INTERNATIONAL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE INCOME

(unaudited)

(dollars in thousands, except per share data)

 
  Three months ended March 31,   Six months ended March 31,  
 
  2010   2011   2010   2011  

Net sales

  $ 47,896   $ 49,549   $ 92,735   $ 94,792  

Cost of sales

    22,553     24,135     43,918     45,916  
                   
 

Gross profit

    25,343     25,414     48,817     48,876  

Operating expenses

                         
 

Selling, general and administrative

    16,679     17,512     33,428     34,247  
 

Amortization of intangible assets

    314     404     612     794  
                   

Income from operations

    8,350     7,498     14,777     13,835  

Interest and other (income) expense, net

    147     338     256     509  
                   

Income before provision for income taxes

    8,203     7,160     14,521     13,326  

Provision for income taxes

    3,102     2,608     5,476     4,827  
                   

Net income

  $ 5,101   $ 4,552   $ 9,045   $ 8,499  

Other comprehensive income (loss)

                         
 

Foreign currency translation adjustment, net of tax

    (77 )   125     (75 )   164  
                   

Comprehensive income

  $ 5,024   $ 4,677   $ 8,970   $ 8,663  
                   

Net income per common share

                         
 

Basic

  $ 0.49   $ 0.44   $ 0.87   $ 0.82  
 

Diluted

    0.49     0.44     0.86     0.81  

Weighted average common shares outstanding

                         
 

Basic

    10,385,927     10,371,037     10,437,342     10,374,816  
 

Dilutive effect of stock options

    92,759     54,527     87,265     69,051  
                   
 

Diluted

    10,478,686     10,425,564     10,524,607     10,443,867  
                   

The accompanying notes are an integral part of these condensed consolidated financial statements.

4


Table of Contents


NUTRACEUTICAL INTERNATIONAL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(dollars in thousands)

 
  Six months ended
March 31,
 
 
  2010   2011  

Cash flows from operating activities

             

Net income

  $ 9,045   $ 8,499  

Adjustments to reconcile net income to net cash provided by operating activities:

             
 

Depreciation and amortization

    3,527     3,975  
 

Amortization of deferred financing fees

    28     65  
 

Losses on disposals of property and equipment

        15  
 

Deferred income taxes

    1,014     923  
 

Changes in assets and liabilities, net of effects of acquisitions

             
   

Accounts receivable, net

    (566 )   (2,135 )
   

Inventories, net

    (5,654 )   2,611  
   

Prepaid expenses and other current assets

    713     336  
   

Other non-current assets

    (1,508 )   185  
   

Accounts payable

    3,869     2,772  
   

Accrued expenses

    (9 )   (1,303 )
   

Other non-current liabilities

    514     (240 )
           
     

Net cash provided by operating activities

    10,973     15,703  
           

Cash flows from investing activities

             

Acquisitions of businesses

    (11,608 )   (7,403 )

Purchases of property and equipment

    (8,206 )   (3,364 )
           
     

Net cash used in investing activities

    (19,814 )   (10,767 )
           

Cash flows from financing activities

             

Proceeds from debt

    17,500     8,000  

Payments on debt

    (5,500 )   (9,000 )

Payments of deferred financing fees

        (878 )

Proceeds from issuances of common stock

    421     660  

Purchases of common stock for treasury

    (2,830 )   (1,933 )

Tax benefit from stock option exercises

    43     250  
           
     

Net cash provided by (used in) financing activities

    9,634     (2,901 )
           

Effect of exchange rate changes on cash and cash equivalents

    (42 )   75  
           

Net increase in cash and cash equivalents

    751     2,110  

Cash and cash equivalents at beginning of period

    5,858     3,740  
           

Cash and cash equivalents at end of period

  $ 6,609   $ 5,850  
           

The accompanying notes are an integral part of these condensed consolidated financial statements.

5


Table of Contents


NUTRACEUTICAL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

(dollars in thousands, except per share data)

1. BASIS OF PRESENTATION

        Nutraceutical International Corporation and its subsidiaries (the "Company") is an integrated manufacturer, marketer, distributor and retailer of branded nutritional supplements and other natural products sold primarily to and through domestic health and natural food stores. Internationally, the Company markets and distributes branded nutritional supplements and other natural products to and through health and natural product distributors and retailers. The Company's core business strategy is to acquire, integrate and operate businesses in the natural products industry that manufacture, market and distribute branded nutritional supplements. The Company believes that the consolidation and integration of these acquired businesses provide ongoing financial synergies through increased scale and market penetration, as well as strengthened customer relationships.

        The Company manufactures and sells nutritional supplements and other natural products under numerous brands including Solaray®, KAL®, Nature's Life®, LifeTime®, Natural Balance®, bioAllers®, Herbs for Kids™, NaturalCare®, Health from the Sun®, Life-flo®, Organix South®, Pioneer® and Monarch Nutraceuticals™.

        The Company owns neighborhood natural food markets, which operate under the trade names The Real Food Company™, Thom's Natural Foods™ and Cornucopia Community Market™. The Company also owns health food stores, which operate under the trade names Fresh Vitamins™ and Granola's™.

        In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all necessary adjustments to present fairly the consolidated financial position of the Company as of March 31, 2011, the results of its operations for the three and six months ended March 31, 2010 and 2011 and its cash flows for the six months ended March 31, 2010 and 2011, in conformity with accounting principles generally accepted in the United States of America for interim financial information applied on a consistent basis. Results for the three and six months ended March 31, 2011 are not necessarily indicative of the results to be expected for the full fiscal year.

        Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted. Accordingly, these financial statements should be read in conjunction with the Company's Form 10-K for the fiscal year ended September 30, 2010, which was filed with the Securities and Exchange Commission on November 23, 2010.

Use of Estimates

        The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America required management to make estimates and assumptions that affected the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of net sales and expenses during the reported periods. Significant estimates included values and lives assigned to acquired intangible assets, reserves for customer returns and allowances, uncollectible accounts receivable, slow moving, obsolete and/or damaged inventory and valuation and recoverability of long-lived assets. Actual results may differ from these estimates.

6


Table of Contents


NUTRACEUTICAL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

(dollars in thousands, except per share data)

1. BASIS OF PRESENTATION (Continued)

New Accounting Standards

        The Company reviews new accounting standards as they are issued. Although some of these accounting standards may be applicable to the Company, the Company has not identified any new standards that the Company believes merit further discussion, and the Company expects that none would have a significant impact on the Company's consolidated financial statements.

2. ACCOUNTS RECEIVABLE, NET

        Accounts receivable, net of allowances for sales returns and doubtful accounts, consisted of the following:

 
  September 30,
2010
  March 31,
2011
 

Accounts receivable

  $ 12,769   $ 15,028  

Less allowances

    (2,101 )   (2,093 )
           

  $ 10,668   $ 12,935  
           

3. INVENTORIES, NET

        Inventories, net of reserves for slow moving, obsolete and/or damaged inventory, were comprised of the following:

 
  September 30,
2010
  March 31,
2011
 

Raw materials

  $ 15,369   $ 16,399  

Work-in-process

    5,117     5,385  

Finished goods

    21,382     18,335  
           

    41,868     40,119  

Less reserves

    (1,595 )   (1,591 )
           

  $ 40,273   $ 38,528  
           

4. ACQUISITIONS

        During the six months ended March 31, 2011, the Company made three acquisitions of businesses. On October 7, 2010, the Company acquired certain operating assets of TRC Nutritional Labs, Inc. On October 14, 2010, the Company acquired certain operating assets of The Heritage Store, Inc. On February 24, 2011, the Company acquired certain operating assets of SunFeather Natural Soap Company, Inc.

        The aggregate purchase price of these acquisitions was $7,403 in cash. The Condensed Consolidated Statements of Operations and the Condensed Consolidated Statements of Cash Flows presented herein include the activities of these acquired businesses from their respective dates of acquisition. The expected long-term sales and expense synergies of acquired businesses generally are

7


Table of Contents


NUTRACEUTICAL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

(dollars in thousands, except per share data)

4. ACQUISITIONS (Continued)


not realized immediately following acquisition as certain transition and integration matters must be completed.

        These acquisitions are in keeping with the Company's business strategy of consolidating the fragmented industry in which it competes and were accounted for using the acquisition method of accounting. Accordingly, the aggregate purchase price was assigned to the assets acquired based on their fair market values at their respective dates of acquisition. The excess of aggregate purchase price over the fair market values of the assets acquired was classified as goodwill. The following reflects the final allocation of the aggregate purchase price for these acquisitions to the aggregate assets acquired:

Current assets

  $ 1,092  

Property, plant and equipment

    4,332  

Goodwill

    823  

Intangible assets

    1,156  
       

  $ 7,403  
       

        The acquired intangible assets include trademarks and tradenames totaling $449 that have indefinite lives and are not subject to amortization, as well as customer relationships totaling $707, which are being amortized for financial statement purposes over three to six years. The acquired intangible assets of $1,156, as well as goodwill of $823, which is not subject to amortization for financial statement purposes, are expected to be deductible for tax purposes over 15 years.

5. GOODWILL AND INTANGIBLE ASSETS

        The change in the carrying amount of goodwill from September 30, 2010 to March 31, 2011 was as follows:

 
  Goodwill  

Balance as of September 30, 2010

       
 

Goodwill

  $ 45,732  
 

Accumulated impairment losses

    (40,394 )
       

    5,338  
 

Goodwill attributable to fiscal 2011 acquisitions

   
823
 
       

Balance as of March 31, 2011

       
 

Goodwill

    46,555  
 

Accumulated impairment losses

    (40,394 )
       

  $ 6,161  
       

8


Table of Contents


NUTRACEUTICAL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

(dollars in thousands, except per share data)

5. GOODWILL AND INTANGIBLE ASSETS (Continued)

        The carrying amounts of intangible assets at September 30, 2010 and March 31, 2011 were as follows:

 
  September 30, 2010   March 31, 2011    
 
 
  Weighted-
Average
Amortization
Period (Years)
 
 
  Gross
Carrying
Amount(1)
  Accumulated
Amortization(1)
  Net
Carrying
Amount
  Gross
Carrying
Amount(1)
  Accumulated
Amortization(1)
  Net
Carrying
Amount
 

Intangible assets subject to amortization:

                                           
 

Trademarks/trade names/patents

  $ 686   $ (466 ) $ 220   $ 705   $ (501 ) $ 204     6  
 

Customer relationships/distribution rights

    7,689     (2,300 )   5,389     8,534     (3,070 )   5,464     6  
 

Developed software and technology

    772     (605 )   167     772     (682 )   90     5  
                                 

    9,147     (3,371 )   5,776     10,011     (4,253 )   5,758        

Intangible assets not subject to amortization:

                                           
 

Trademarks/trade names/licenses

    13,895         13,895     14,385         14,385        
                                 

  $ 23,042   $ (3,371 ) $ 19,671   $ 24,396   $ (4,253 ) $ 20,143        
                                 

(1)
Amounts include the impact of foreign currency translation adjustments.

        Estimated future amortization expense related to the March 31, 2011 net carrying amount of $5,758 for intangible assets subject to amortization is as follows:

Year Ending September 30,
  Estimated
Amortization
Expense
 

2011(1)

  $ 811  

2012

    1,460  

2013

    1,252  

2014

    994  

2015

    888  

Thereafter

    353  
       

  $ 5,758  
       

(1)
Estimated amortization expense for the year ending September 30, 2011 includes only amortization to be recorded after March 31, 2011.

9


Table of Contents


NUTRACEUTICAL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

(dollars in thousands, except per share data)

6. DEBT

        Debt was comprised of the following:

 
  September 30,
2010
  March 31,
2011
 

Short-term debt—revolving credit facility

  $ 28,000   $  

Long-term debt—revolving credit facility

        27,000  
           

  $ 28,000   $ 27,000  
           

        The Company's debt is stated at book value which approximated its fair value at September 30, 2010 and March 31, 2011.

        On December 17, 2010, the Company amended and restated its revolving credit facility (the "Restated Credit Agreement"). The Restated Credit Agreement extends the term of the credit facility to December 2015, resets the available credit borrowings to $90,000 with no automatic reductions and provides an accordion feature which can increase the available credit borrowings to $120,000 subject to approval by the lenders and compliance with certain covenants and conditions. The lenders under the Restated Credit Agreement are Rabobank International and Wells Fargo. To date, the Company has not experienced any difficulties in accessing the available funds under the Restated Credit Agreement. Deferred financing fees of $878 related to the Restated Credit Agreement were deferred and are being amortized over the term of the Restated Credit Agreement. The Company's previous revolving credit facility would have matured on September 7, 2011. Therefore, the balance outstanding at September 30, 2010 was classified in current liabilities.

        At March 31, 2011, the Company had outstanding revolving credit borrowings of $27,000 under the Restated Credit Agreement. Borrowings under the Restated Credit Agreement are collateralized by substantially all assets of the Company. At the Company's election, borrowings bear interest at the applicable Eurodollar Rate plus a variable margin or at a base rate, which is the higher of the Federal Funds Rate plus 0.5% or the Prime Lending Rate, plus a variable margin. At March 31, 2011, the applicable weighted-average interest rate for outstanding borrowings was 2.31%. The Company is also required to pay a quarterly fee of 0.50% on the unused balance under the Restated Credit Agreement. Accrued interest on Eurodollar Rate borrowings is payable based on elected intervals of one, two or three months. Accrued interest on base rate borrowings is payable quarterly. The Restated Credit Agreement matures on December 15, 2015, and the Company is required to repay all principal and interest outstanding under the Restated Credit Agreement on such date.

        The Restated Credit Agreement contains restrictive covenants, including limitations on incurring other indebtedness and requirements that the Company maintain certain financial ratios. Upon the occurrence of a default, the lender has various remedies or rights, which may include proceeding against the collateral or requiring the Company to repay all amounts outstanding under the Restated Credit Agreement.

10


Table of Contents


NUTRACEUTICAL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

(dollars in thousands, except per share data)

7. SHARE REPURCHASES

        During the three and six months ended March 31, 2011, the Company purchased and retired 135,771 shares of common stock for an aggregate price of $1,933. During the three months ended March 31, 2010, the Company purchased and retired 50,100 shares of common stock for an aggregate price of $605. During the six months ended March 31, 2010, the Company purchased and retired 239,409 shares of common stock for an aggregate price of $2,830. As of March 31, 2011, the Company was permitted to purchase up to 744,021 additional shares under its approved purchase plan. The Company accounts for treasury shares using the cost method.

8. STOCK OPTIONS

        The following table summarizes stock option activity during the six months ended March 31, 2011:

 
  Number of
Options
  Weighted-Average
Exercise Price
 

Options outstanding and exercisable at September 30, 2010

    391,688   $ 9.64  

Exercised

    (67,888 )   6.12  
             

Options outstanding and exercisable at March 31, 2011

    323,800   $ 10.38  
             

        Options to purchase 52,500 and 142,650 shares of common stock for the three and six months ended March 31, 2010, respectively, were excluded from the computation of diluted earnings per share because the exercise prices of these stock options were greater than the average share price of the Company's common stock and, therefore, the effect would have been antidilutive.

        During the six months ended March 31, 2011, the Company received proceeds of $416 related to the exercise of stock options. During this same period, the Company recorded a tax benefit of $250 and optionees realized an aggregate pre-tax gain of $648 from these stock option exercises. During the six months ended March 31, 2010, the Company received proceeds of $55 related to the exercise of stock options. During this same period, the Company recorded a tax benefit of $43 and optionees realized an aggregate pre-tax gain of $112 from these stock option exercises.

9. SEGMENTS

        Segment identification and selection is consistent with the management structure used by the Company to evaluate performance and make decisions regarding resource allocation, as well as the materiality of financial results consistent with that structure. Based on the Company's management structure and method of internal reporting, the Company has one operating segment. The Company does not review operating results on a disaggregated basis; rather, management reviews operating results on an aggregate basis.

11


Table of Contents


NUTRACEUTICAL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(unaudited)

(dollars in thousands, except per share data)

9. SEGMENTS (Continued)

        Net sales attributed to customers in the United States and foreign countries for the three and six months ended March 31, 2010 and 2011 were as follows:

 
  Three months ended
March 31,
  Six months ended
March 31,
 
 
  2010   2011   2010   2011  

United States

  $ 41,933   $ 44,422   $ 81,958   $ 85,094  

Foreign countries

    5,963     5,127     10,777     9,698  
                   

  $ 47,896   $ 49,549   $ 92,735   $ 94,792  
                   

        Certain net sales attributed to customers in the United States are sold to customers who in turn may sell such products to customers in foreign countries while certain net sales attributed to customers in foreign countries are sold to customers who in turn may sell such products to customers in the United States.

        The Company's net sales by product group for the three and six months ended March 31, 2010 and 2011 were as follows:

 
  Three months ended
March 31,
  Six months ended
March 31,
 
 
  2010   2011   2010   2011  

Branded nutritional supplements and other natural products

  $ 43,963   $ 45,653   $ 84,908   $ 87,140  

Other(1)

    3,933     3,896     7,827     7,652  
                   

  $ 47,896   $ 49,549   $ 92,735   $ 94,792  
                   

(1)
Net sales for any other product or group of similar products are less than 10% of consolidated net sales.

12


Table of Contents

Item 2.    Management's Discussion and Analysis of Financial Condition and Results of Operations

General

        The following discussion and analysis should be read in conjunction with the other sections of this report on Form 10-Q, including Part I, Item 1.

        We are an integrated manufacturer, marketer, distributor and retailer of branded nutritional supplements and other natural products sold primarily to and through domestic health and natural food stores. Internationally, we market and distribute branded nutritional supplements and other natural products to and through health and natural product distributors and retailers. Our core business strategy is to acquire, integrate and operate businesses in the natural products industry that manufacture, market and distribute branded nutritional supplements. We believe that the consolidation and integration of these acquired businesses provide ongoing financial synergies through increased scale and market penetration, as well as strengthened customer relationships.

        We manufacture and sell nutritional supplements and other natural products under numerous brands including Solaray®, KAL®, Nature's Life®, LifeTime®, Natural Balance®, bioAllers®, Herbs for Kids™, NaturalCare®, Health from the Sun®, Life-flo®, Organix South®, Pioneer® and Monarch Nutraceuticals™.

        We own neighborhood natural food markets, which operate under the trade names The Real Food Company™, Thom's Natural Foods™ and Cornucopia Community Market™. We also own health food stores, which operate under the trade names Fresh Vitamins™ and Granola's™.

        We were formed in 1993 to effect a consolidation strategy in the fragmented vitamin, mineral, herbal and other nutritional supplements industry (the "VMS Industry"). Since our formation, we have completed thirty-three acquisitions of assets or stock. As a result of acquisitions, internal growth and cost management, we believe that we are well positioned to continue to capitalize on acquisition opportunities that arise in the VMS Industry.

Critical Accounting Policies

        The preparation of our financial statements in conformity with accounting principles generally accepted in the United States of America required us to make estimates and assumptions that affected the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of net sales and expenses during the reported periods. Significant estimates included values and lives assigned to acquired intangible assets, reserves for customer returns and allowances, uncollectible accounts receivable, slow moving, obsolete and/or damaged inventory and valuation and recoverability of long-lived assets. Actual results may differ from these estimates. Our critical accounting policies include the following:

        Accounts Receivable—Provision is made for estimated bad debts based on periodic analysis of individual customer balances, including an evaluation of days sales outstanding, payment history, recent payment trends and perceived credit worthiness. If general economic conditions and/or customer financial condition were to change, additional provisions for bad debts may be required, which could have a material impact on the consolidated financial statements.

        Inventories—Provision is made for slow moving, obsolete and/or damaged inventory based on periodic analysis of individual inventory items, including an evaluation of historical usage and/or movement, age, expiration date and general condition. If market demand and/or consumer preferences are less favorable than historical trends or future expectations, additional provisions for slow moving, obsolete and/or damaged inventory may be required, which could have a material impact on the consolidated financial statements.

13


Table of Contents

        Property, Plant and Equipment—Depreciation and amortization expense is impacted by our judgments regarding the estimated useful lives of assets placed in service. If the actual lives of assets are significantly less than expected, depreciation and amortization expense would be accelerated, which could have a material impact on the consolidated financial statements.

        We evaluate the recoverability of our property, plant and equipment which are reviewed for possible impairment whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. We measure recoverability of the asset by comparison of its carrying amount to the future undiscounted cash flows we expect the asset to generate. If we consider the asset to be impaired, we measure the amount of any impairment as the difference between the carrying amount and the fair value of the impaired asset.

        Goodwill and Intangible Assets—Goodwill and intangible assets require estimates and a high degree of judgment in determining the initial recognition and measurement of goodwill and intangible assets, including factors and assumptions used in determining fair values and useful lives. Intangible assets with finite useful lives are amortized, while intangible assets with indefinite useful lives are not amortized. Amortizable intangible assets are reviewed for impairment when events or changes in circumstances indicate the carrying value may not be recoverable. Goodwill and non-amortizable intangible assets are tested annually for impairment and are tested for impairment between annual tests if an event occurs that would cause us to believe that value is impaired. Events that could trigger an impairment include changes in general and economic conditions that impact retail and consumer demand, as well as the market price of our common stock. Such events could negatively impact our future operating performance, cash flow and/or stock price and could result in goodwill and/or intangible asset impairment charges which could materially impact our consolidated financial statements. We perform our annual impairment testing as of September 30 each year, which is the last day of our fiscal year.

        Revenue Recognition—Revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the product has been shipped and the customer takes ownership and assumes the risk of loss; (3) the selling price is fixed or determinable; and (4) collection of the resulting receivable is reasonably assured. We believe that these criteria are satisfied upon shipment from our facilities or, in the case of our neighborhood natural food markets and health food stores, at the point of sale within these stores. Revenue is reduced by provisions for estimated returns and allowances, which are based on historical averages that have not varied significantly for the periods presented, as well as specific known claims, if any. No other significant deductions from revenue must be estimated at the point in time that revenue is recognized.

        Our estimates and judgments related to our critical accounting policies, including factors and assumptions considered in making these estimates and judgments, did not vary significantly for the periods presented and had no material impact on the consolidated financial statements as reported.

New Accounting Standards

        See Note 1 to the Condensed Consolidated Financial Statements for information regarding new accounting standards.

14


Table of Contents

Results of Operations

        The following table sets forth certain consolidated statements of operations data as a percentage of net sales for the periods indicated:

 
  Three Months
Ended
March 31,
  Six Months
Ended
March 31,
 
 
  2010   2011   2010   2011  

Net sales

    100.0 %   100.0 %   100.0 %   100.0 %
 

Cost of sales

    47.1 %   48.7 %   47.4 %   48.4 %
                   

Gross profit

    52.9 %   51.3 %   52.6 %   51.6 %
 

Selling, general and administrative

    34.8 %   35.3 %   36.0 %   36.1 %
 

Amortization of intangible assets

    0.7 %   0.8 %   0.7 %   0.8 %
                   

Income from operations

    17.4 %   15.2 %   15.9 %   14.7 %
 

Interest and other (income) expense, net

    0.3 %   0.7 %   0.2 %   0.6 %
                   

Income before provision for income taxes

    17.1 %   14.5 %   15.7 %   14.1 %
 

Provision for income taxes

    6.5 %   5.3 %   5.9 %   5.1 %
                   

Net income

    10.6 %   9.2 %   9.8 %   9.0 %
                   

EBITDA(1)

    21.1 %   19.2 %   19.7 %   18.8 %
                   

(1)
See "—EBITDA."

Comparison of the Three Months Ended March 31, 2011 to the Three Months Ended March 31, 2010

        Net Sales.    Net sales increased by $1.6 million, or 3.5%, to $49.5 million for the three months ended March 31, 2011 ("second quarter of fiscal 2011") from $47.9 million for the three months ended March 31, 2010 ("second quarter of fiscal 2010"). Net sales of branded nutritional supplements and other natural products increased by $1.6 million, or 3.8%, to $45.6 million for the second quarter of fiscal 2011 compared to $44.0 million for the second quarter of fiscal 2010. The increase in net sales of branded nutritional supplements and other natural products was primarily related to the net sales contributions of the fiscal 2010 and fiscal 2011 acquisitions, partially offset by a decrease in sales volume of branded products to certain customers. The impact on net sales of branded products attributable to price changes was not material. Other net sales were $3.9 million for both the second quarter of fiscal 2011 and the second quarter of fiscal 2010.

        Gross Profit.    Gross profit was $25.4 million for the second quarter of fiscal 2011 and $25.3 million for the second quarter of fiscal 2010. As a percentage of net sales, gross profit decreased to 51.3% for the second quarter of fiscal 2011 from 52.9% for the second quarter of fiscal 2010. This decrease in gross profit percentage was primarily attributable to increased manufacturing overhead costs related to the expansion of our liquid manufacturing operations, partially offset by a decrease in material costs due to vendor price decreases and changes in sales mix.

        Selling, General and Administrative.    Selling, general and administrative expenses increased by $0.8 million, or 5.0%, to $17.5 million for the second quarter of fiscal 2011 from $16.7 million for the second quarter of fiscal 2010. As a percentage of net sales, selling, general and administrative expenses increased to 35.3% for the second quarter of fiscal 2011 compared to 34.8% for the second quarter of fiscal 2010. This increase in selling, general and administrative expenses was primarily attributable to operational and transition costs related to the fiscal 2011 acquisitions.

15


Table of Contents

        Amortization of Intangible Assets.    Amortization of intangible assets was $0.4 million for the second quarter of fiscal 2011 and $0.3 million for the second quarter of fiscal 2010. For each period, amortization expense was primarily related to intangible assets recorded in connection with acquisitions.

        Interest and Other (Income) Expense, Net.    Net interest and other (income) expense was $0.3 million for the second quarter of fiscal 2011 and $0.1 million for the second quarter of fiscal 2010 and primarily consisted of interest expense on indebtedness under our revolving credit facility with the increase being primarily related to an increase in interest rates.

        Provision for Income Taxes.    Our effective tax rate was 36.4% for the second quarter of fiscal 2011 and 37.8% for the second quarter of fiscal 2010. The decrease in the effective tax rate was primarily due to an increase in the domestic production deduction rate. In each period, our effective tax rate was higher than the federal statutory rate primarily due to state taxes.

Comparison of the Six Months Ended March 31, 2011 to the Six Months Ended March 31, 2010

        Net Sales.    Net sales increased by $2.1 million, or 2.2%, to $94.8 million for the six months ended March 31, 2011 from $92.7 million for the six months ended March 31, 2010. Net sales of branded nutritional supplements and other natural products increased by $2.2 million, or 2.6%, to $87.1 million for the six months ended March 31, 2011 compared to $84.9 million for the six months ended March 31, 2010. The increase in net sales of branded nutritional supplements and other natural products was primarily related to the net sales contributions of the fiscal 2010 and fiscal 2011 acquisitions, partially offset by a decrease in sales volume of branded products to certain customers. The impact on net sales of branded products attributable to price changes was not material. Other net sales were $7.7 million for the six months ended March 31, 2011 compared to $7.8 million for the six months ended March 31, 2010.

        Gross Profit.    Gross profit was $48.9 million for the six months ended March 31, 2011 and $48.8 million for the six months ended March 31, 2010. As a percentage of net sales, gross profit decreased to 51.6% for the six months ended March 31, 2011 from 52.6% for the six months ended March 31, 2010. This decrease in gross profit percentage was primarily attributable to increased manufacturing overhead costs related to the expansion of our liquid manufacturing operations, partially offset by a decrease in material costs due to vendor price decreases and changes in sales mix.

        Selling, General and Administrative.    Selling, general and administrative expenses increased by $0.8 million, or 2.5%, to $34.2 million for the six months ended March 31, 2011 from $33.4 million for the six months ended March 31, 2010. This increase in selling, general and administrative expenses was primarily attributable to operational and transition costs related to the fiscal 2011 acquisitions. As a percentage of net sales, selling, general and administrative expenses were 36.1% for the six months ended March 31, 2011 compared to 36.0% for the six months ended March 31, 2010.

        Amortization of Intangible Assets.    Amortization of intangibles was $0.8 million for the six months ended March 31, 2011 and $0.6 million for the six months ended March 31, 2010. For each period, amortization expense was primarily related to intangible assets recorded in connection with acquisitions.

        Interest and Other (Income) Expense, Net.    Net interest and other (income) expense was $0.5 million for the six months ended March 31, 2011 and $0.3 million for the six months ended March 31, 2010 and primarily consisted of interest expense on indebtedness under our revolving credit facility with the increase being primarily related to an increase in interest rates.

        Provision (Benefit) for Income Taxes.    Our effective tax rate was 36.2% for the six months ended March 31, 2011 and 37.7% for the six months ended March 31, 2010. The decrease in the effective tax rate was primarily due to an increase in the domestic production deduction rate. In each period, our effective tax rate was higher than the federal statutory rate primarily due to state taxes.

16


Table of Contents

EBITDA

        EBITDA (a non-GAAP measure) is defined in our debt covenants and performance measures as earnings before net interest and other (income) expense, taxes, depreciation and amortization. EBITDA has some inherent limitations in measuring operating performance due to the exclusion of certain financial elements such as depreciation and amortization and is not necessarily comparable to other similarly-titled captions of other companies due to potential inconsistencies in the method of calculation. Furthermore, EBITDA is not intended to be a substitute for cash flows from operating activities, as a measure of liquidity, or an alternative to net income in determining our operating performance in accordance with generally accepted accounting principles. Our use of an EBITDA-based metric should be considered within the following context:

    We acknowledge that plant and equipment (while less important in our line of business due to outsourcing alternatives) are necessary to earn revenue based on our current business model.

    Our use of an EBITDA-based measure of operating performance is not based on any belief about the reasonableness of excluding depreciation and amortization when measuring financial performance.

    Our use of an EBITDA-based measure is supported by its importance to the following key stakeholders:

    Analysts—who estimate our projected EBITDA and other EBITDA-based metrics in their independently developed financial models for investors;

    Creditors—who evaluate our operating performance based on compliance with certain EBITDA-based debt covenants;

    Investment Bankers—who use EBITDA-based metrics in their written evaluations and comparisons of companies within our industry; and

    Board of Directors and Executive Management—who use EBITDA-based metrics for evaluating management performance relative to our operating budget and bank covenant compliance, as well as our ability to service debt and raise capital for growth opportunities, including acquisitions, which are a critical component of our stated strategy. Historically, we have recorded a monthly accrual for incentive compensation as a percentage of EBITDA, which has been paid out to executive management, as well as other employees, upon completion of our annual audit.

        The following table sets forth a reconciliation of net income to EBITDA for each period included herein:

 
  Three Months Ended
March 31,
  Six Months Ended
March 31,
 
 
  2010   2011   2010   2011  
 
  (dollars in thousands)
 

Net income

  $ 5,101   $ 4,552   $ 9,045   $ 8,499  

Provision for income taxes

    3,102     2,608     5,476     4,827  

Interest and other (income) expense, net(1)

    147     338     256     509  

Depreciation and amortization

    1,767     2,033     3,527     3,975  
                   

EBITDA

  $ 10,117   $ 9,531   $ 18,304   $ 17,810  
                   

(1)
Includes amortization of deferred financing fees.

17


Table of Contents

        Our EBITDA decreased to $9.5 million for the second quarter of fiscal 2011 from $10.1 million for the second quarter of fiscal 2010. EBITDA as a percentage of net sales decreased to 19.2% for the second quarter of fiscal 2011 from 21.1% for the second quarter of fiscal 2010.

        Our EBITDA decreased to $17.8 million for the six months ended March 31, 2011 from $18.3 million for the six months ended March 31, 2010. EBITDA as a percentage of net sales decreased to 18.8% for the six months ended March 31, 2011 from 19.7% for the six months ended March 31, 2010.

Seasonality

        We believe that our business is characterized by minor seasonality. However, sales to any particular customer or sales of any particular product can vary substantially from one quarter to the next based on such factors as industry trends, timing of promotional discounts, domestic and international economic conditions and acquisition-related activities. Excluding the effect of acquisitions, we have historically recorded higher branded products sales volume during the second fiscal quarter (January through March) due to increased interest in health-related products among consumers following the holiday season.

Liquidity and Capital Resources

        We had working capital of $41.6 million as of March 31, 2011 compared to $12.6 million as of September 30, 2010. This increase in working capital was primarily the result of debt related to our revolving credit facility being classified as a non-current liability at March 31, 2011 as compared to a current liability at September 30, 2010 based on the amendment and restatement of our revolving credit facility on December 17, 2010. The increase in working capital was also the result of increases in cash and accounts receivable and a decrease in accrued expenses partially offset by a decrease in inventories and an increase in accounts payable.

        Net cash provided by operating activities for the six months ended March 31, 2011 was $15.7 million compared to $11.0 million for the comparable period in fiscal 2010. This increase in net cash provided by operating activities for the six months ended March 31, 2011 was primarily attributable to changes in assets and liabilities, net of effects of acquisitions.

        Net cash used in investing activities was $10.8 million for the six months ended March 31, 2011 compared to $19.8 million for the comparable period in fiscal 2010. Our investing activities during these periods consisted of acquisitions of businesses and capital expenditures. Capital expenditures primarily related to building improvements related to facility consolidation efforts, distribution and manufacturing equipment and information systems.

        During the six months ended March 31, 2011, we acquired three businesses for $7.4 million in cash. On October 7, 2010, we acquired certain operating assets of TRC Nutritional Labs, Inc. On October 14, 2010, we acquired certain operating assets of The Heritage Store, Inc. On February 24, 2011, we acquired certain operating assets of SunFeather Natural Soap Company, Inc. During the six months ended March 31, 2010, we acquired two businesses for $11.6 million in cash. On October 9, 2009, we acquired selected assets of Nutritional Specialties, Inc. On December 18, 2009, we acquired selected assets of Organix-South, Inc.

        Net cash used in financing activities was $2.9 million for the six months ended March 31, 2011 compared to net cash provided by financing activities of $9.6 million for the comparable period in fiscal 2010. During these periods, financing activities primarily related to borrowings and repayments under our revolving credit facility, payments of deferred financing fees, purchases of common stock for treasury and proceeds from the issuance of common stock related to stock option exercises and the direct stock purchase plan.

18


Table of Contents

        In October 2007, we registered a direct stock purchase plan with the Securities and Exchange Commission. The purpose of this direct stock purchase plan is to provide a convenient way for existing stockholders, as well as new investors, to purchase shares of our common stock. A total of 1,500,000 shares of our common stock were registered under the plan with 17,537 shares purchased during the six months ended March 31, 2011. As of March 31, 2011, there were 1,414,364 shares of common stock available for purchase.

        On December 17, 2010, we amended and restated our revolving credit facility (the "Restated Credit Agreement"). The Restated Credit Agreement extends the term of the credit facility to December 2015, resets the available credit borrowings to $90 million with no automatic reductions and provides an accordion feature which can increase the available credit borrowings to $120 million subject to approval by the lenders and compliance with certain covenants and conditions. The lenders under the Restated Credit Agreement are Rabobank International and Wells Fargo. To date, we have not experienced any difficulties in accessing the available funds under the Restated Credit Agreement. Deferred financing fees of $0.9 million related to the Restated Credit Agreement were deferred and are being amortized over the term of the Restated Credit Agreement.

        At March 31, 2011, we had outstanding revolving credit borrowings of $27.0 million under the Restated Credit Agreement. Borrowings under the Restated Credit Agreement are collateralized by substantially all of our assets. At our election, borrowings bear interest at the applicable Eurodollar Rate plus a variable margin or at a base rate, which is the higher of the Federal Funds Rate plus 0.5% or the Prime Lending Rate, plus a variable margin. At March 31, 2011, the applicable weighted-average interest rate for outstanding borrowings was 2.31%. We are also required to pay a quarterly fee of 0.50% on the unused balance under the Restated Credit Agreement. Accrued interest on Eurodollar Rate borrowings is payable based on elected intervals of one, two or three months. Accrued interest on base rate borrowings is payable quarterly. The Restated Credit Agreement matures on December 15, 2015, and we are required to repay all principal and interest outstanding under the Restated Credit Agreement on such date.

        The Restated Credit Agreement contains restrictive covenants, including limitations on incurring certain other indebtedness and requirements that we maintain certain financial ratios. As of March 31, 2011, we were in compliance with the restrictive covenants. Upon the occurrence of a default, the lender has various remedies or rights, which may include proceeding against the collateral or requiring us to repay all amounts outstanding under the Restated Credit Agreement.

        A key component of our business strategy is to seek to make additional acquisitions, which may require that we obtain additional financing, which could include the incurrence of substantial additional indebtedness or the issuance of additional stock. We believe that borrowings under our current revolving credit facility or a replacement credit facility, together with cash flows from operations, will be sufficient to make required payments under the current credit facility or any such replacement facility, and to make anticipated capital expenditures and fund working capital needs for the next twelve months.

19


Table of Contents

Contractual Obligations and Other Commitments

        Our significant non-cancelable contractual obligations and other commitments as of March 31, 2011 were as follows:

 
  Payments Due By Period  
Contractual Obligations and Other Commitments
  Total   Less Than
1 Year
  1 - 3
Years
  4 - 5
Years
  After
5 Years
 
 
  (dollars in thousands)
 

Revolving credit facility

  $ 27,000   $   $   $ 27,000   $  

Interest on revolving credit facility(a)

    4,603     977     1,954     1,672      

Operating leases

    5,122     2,752     2,007     332     31  
                       

Total

  $ 36,725   $ 3,729   $ 3,961   $ 29,004   $ 31  
                       

(a)
Represents estimated interest obligations associated with our outstanding revolving credit facility balance of $27.0 million at March 31, 2011, assuming no principal payments are made before maturity, a weighted-average interest rate of 2.31% and an underutilization fee rate of 0.50%.

Inflation

        Inflation affects the cost of raw materials, goods and services used by us. In recent years, inflation has been modest. The competitive environment somewhat limits our ability to recover higher costs resulting from inflation by raising prices. We seek to mitigate the adverse effects of inflation primarily through improved productivity and cost containment programs. We do not believe that inflation has had a material impact on our results of operations for the periods presented, except with respect to increased costs in manufacturing, packaging and distribution resulting from increased fuel and other petrochemical costs, as well as payroll-related costs, insurance premiums and other costs arising from or related to government imposed regulations.

Forward-Looking Statements

        This Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to our financial condition, results of operations and business. These forward-looking statements can be identified by the use of terms such as "believe," "expects," "plan," "intend," "may," "will," "should," "can," or "anticipates," or the negative thereof, or variations thereon, or comparable terminology, or by discussions of strategy. These statements involve known and unknown risks, uncertainties and other factors that may cause industry trends or our actual results to be materially different from any future results expressed or implied by these statements. Important factors that may cause our results to differ from these forward-looking statements include, but are not limited to: (i) changes in or new government regulations or increased enforcement of the same, (ii) unavailability of desirable acquisitions or inability to complete them, (iii) increased costs, including from increased raw material or energy prices, (iv) changes in general worldwide economic or political conditions, (v) adverse publicity or negative consumer perception regarding nutritional supplements, (vi) issues with obtaining raw materials of adequate quality or quantity, (vii) litigation and claims, including product liability, intellectual property and other types, (viii) disruptions from or following acquisitions including the loss of customers, (ix) increased competition, (x) slow or negative growth in the nutritional supplement industry or the healthy foods channel, (xi) the loss of key personnel or the inability to manage our operations efficiently, (xii) problems with information management systems, manufacturing efficiencies and operations, (xiii) insurance coverage issues, (xiv) the volatility of the stock market generally and of our stock specifically, (xv) increases in the cost of borrowings or unavailability of additional debt or equity capital, or both, or fluctuations in foreign

20


Table of Contents


currencies, and (xvi) interruption of business or negative impact on sales and earnings due to acts of God, acts of war, terrorism, bio-terrorism, civil unrest and other factors outside of our control.

        We undertake no obligation to update or revise publicly any forward-looking statements to reflect new information, events or circumstances occurring after the date of this Form 10-Q.

Item 3.    Quantitative and Qualitative Disclosures about Market Risk

        At our election, borrowings under the Restated Credit Agreement bear interest at the applicable Eurodollar Rate plus a variable margin or at a base rate, which is the higher of the Federal Funds Rate plus 0.5% or the Prime Lending Rate, plus a variable margin. At March 31, 2011, the applicable weighted-average interest rate for borrowings was 2.31% and we had total borrowings outstanding of $27.0 million.

        With respect to our international operations, we are subject to currency fluctuations; however, we do not believe that these fluctuations would have a material adverse impact on our financial position because the majority of our net sales to foreign countries are transacted in U.S. dollars. Net sales to foreign countries not transacted in U.S. dollars include sales to customers in Norway, Sweden, the U.K., the Netherlands and Japan. To date, we have not hedged any of our potential foreign currency exposures.

Item 4.    Controls and Procedures

        Evaluation of Disclosure Controls and Procedures.    We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriate, to allow for timely decisions regarding required disclosure.

        In designing and evaluating the disclosure controls and procedures, we recognize that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and we are required to apply our judgment in evaluating the cost-benefit relationship of possible controls and procedures.

        As required by SEC Rule 13a-15(b), we carried out an evaluation, under the supervision of and with the participation of our management, including our principal executive and principal financial officers, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our principal executive and principal financial officers have concluded that our disclosure controls and procedures were effective.

        Changes in Internal Control Over Financial Reporting.    There were no changes in our internal control over financial reporting that occurred during the last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

21


Table of Contents

PART II—OTHER INFORMATION

Item 1.    Legal Proceedings

        As discussed in our other filings, we are subject to regulation by a number of federal, state and foreign agencies and are involved in various legal matters arising in the normal course of business.

        We carry insurance coverage in the types and amounts that we consider reasonably adequate to cover the risks we face in the industry in which we compete.

        In our opinion, the outcomes of individual regulatory and legal matters in which we are presently involved are not probable and no estimate can be made of the range of potential gains or losses. While incapable of estimation, in the opinion of management, the individual regulatory and legal matters in which we are involved are not expected to have a material adverse effect on our consolidated financial position, results of operations or cash flows.

Item 1A.    Risk Factors

        There have been no material changes in our risk factors from those disclosed in our 2010 Annual Report on Form 10-K.

Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds

        We did not sell any unregistered equity securities during the quarterly period ended March 31, 2011.

        Prior to fiscal 2010, our Board of Directors approved a share purchase program authorizing us to buy up to 3,500,000 shares of our common stock. As of March 31, 2011, there were 744,021 shares available for purchase under this program. The shares available for purchase under this program have no expiration date. Purchases under this program during the three months ended March 31, 2011 occurred in January, February and March as follows:

Period
  Total
Number
of Shares
Purchased
  Average
Price
Paid Per
Share
  Total
Number
of Shares
Purchased
as Part of
Publicly
Announced
Plan
  Maximum
Number of
Shares that
May Yet Be
Purchased
Under
the Plan
 

January 1 - 31, 2011

    3,725   $ 14.07     3,725        

February 1 - 28, 2011

    89,550     14.16     89,550        

March 1 - 31, 2011

    42,496     14.42     42,496        
                       

    135,771   $ 14.24     135,771     744,021  
                     

Item 6.    Exhibits

  31.1   Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

32.1

 

Certifications Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

22


Table of Contents


SIGNATURE

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NUTRACEUTICAL INTERNATIONAL CORPORATION
(Registrant)

Date: April 28, 2011   By:   /s/ CORY J. MCQUEEN

Cory J. McQueen
Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer
and Duly Authorized Officer)

23